% ============================================================================
% CONSTRAINT STORY: alzheimers_levetiracetam
% ============================================================================
% Version: 1.0 (Deferential Realism Core + Directionality + Boltzmann + Network)
% Logic: 6.0 (Indexed Tuple P,T,E,S + Sigmoid f(d) + Coupling + Purity + Network)
% Generated: 2024-07-28
% Status: [ACTIVE]
% ============================================================================

:- module(constraint_alzheimers_levetiracetam, []).

:- use_module(constraint_indexing).
:- use_module(domain_priors).
:- use_module(narrative_ontology).

% --- Constraint Identity Rule (DP-001: ε-Invariance) ---
% Each constraint story must have a single, stable base extractiveness (ε).
% If changing the observable used to evaluate this constraint would change ε,
% you are looking at two distinct constraints. Write separate .pl files for
% each, link them with affects_constraint/2, and document the relationship
% in both files' narrative context sections.
%
% The context tuple is CLOSED at arity 4: (P, T, E, S).
% Do not add measurement_basis, beneficiary/victim, or any other arguments.
% Linter Rule 23 enforces context/4.
%
% See: epsilon_invariance_principle.md

% --- Namespace Hooks (Required for loading) ---
:- multifile
    domain_priors:base_extractiveness/2,
    domain_priors:suppression_score/2,
    domain_priors:theater_ratio/2,
    domain_priors:requires_active_enforcement/1,
    narrative_ontology:has_sunset_clause/1,
    narrative_ontology:interval/3,
    narrative_ontology:measurement/5,
    narrative_ontology:constraint_metric/3,
    narrative_ontology:constraint_beneficiary/2,
    narrative_ontology:constraint_victim/2,
    narrative_ontology:constraint_claim/2,
    narrative_ontology:affects_constraint/2,
    narrative_ontology:coordination_type/2,
    constraint_indexing:constraint_classification/3,
    narrative_ontology:omega_variable/3,
    narrative_ontology:human_readable/2,
    narrative_ontology:topic_domain/2.

/* ==========================================================================
   1. NARRATIVE CONTEXT
   ========================================================================== */

/**
 * CONSTRAINT IDENTIFICATION
 *   constraint_id: alzheimers_levetiracetam
 *   human_readable: Levetiracetam as Alzheimer's Preventative
 *   domain: social/medical_policy
 *
 * SUMMARY:
 *   The proposal to use levetiracetam, a cheap, off-patent anti-seizure drug,
 *   as a mass preventative for Alzheimer's disease creates a complex
 *   structural conflict. While it offers a potential low-cost, high-impact
 *   public health intervention (a coordination function), its adoption would
 *   simultaneously threaten the multi-billion dollar market for novel,
 *   patent-protected Alzheimer's drugs currently in development. This creates
 *   a powerful extractive pressure on pharmaceutical R&D, potentially
 *   chilling future innovation. The constraint is not the drug itself, but
 *   the policy choice of its widespread adoption based on promising but
 *   incomplete evidence.
 *
 * KEY AGENTS:
 *   - At-Risk Patients: Primary beneficiaries (organized/mobile) who gain access to a cheap potential preventative.
 *   - Novel Drug Developers: Primary victims (institutional/constrained) whose future market is suppressed by a generic alternative.
 *   - Public Health Systems: Secondary beneficiaries who could save trillions in long-term care costs.
 *   - Regulatory Agencies: Institutional actors (institutional/constrained) who must balance immediate public demand against long-term evidence standards.
 */

/* ==========================================================================
   2. BASE PROPERTIES (DOMAIN PRIORS)
   ========================================================================== */

% --- Numerical metrics ---
domain_priors:base_extractiveness(alzheimers_levetiracetam, 0.55).
domain_priors:suppression_score(alzheimers_levetiracetam, 0.65).
domain_priors:theater_ratio(alzheimers_levetiracetam, 0.2).

% --- Constraint metric facts (engine primary keys, must mirror domain_priors) ---
narrative_ontology:constraint_metric(alzheimers_levetiracetam, extractiveness, 0.55).
narrative_ontology:constraint_metric(alzheimers_levetiracetam, suppression_requirement, 0.65).
narrative_ontology:constraint_metric(alzheimers_levetiracetam, theater_ratio, 0.2).

% --- Constraint claim ---
narrative_ontology:constraint_claim(alzheimers_levetiracetam, tangled_rope).
narrative_ontology:human_readable(alzheimers_levetiracetam, "Levetiracetam as Alzheimer's Preventative").
narrative_ontology:topic_domain(alzheimers_levetiracetam, "social/medical_policy").

domain_priors:requires_active_enforcement(alzheimers_levetiracetam).

% --- Structural relationships ---
narrative_ontology:constraint_beneficiary(alzheimers_levetiracetam, at_risk_patients).
narrative_ontology:constraint_beneficiary(alzheimers_levetiracetam, public_health_systems).
narrative_ontology:constraint_beneficiary(alzheimers_levetiracetam, generic_drug_manufacturers).
narrative_ontology:constraint_victim(alzheimers_levetiracetam, novel_drug_developers).
narrative_ontology:constraint_victim(alzheimers_levetiracetam, patients_with_side_effects_and_no_benefit).

/* ==========================================================================
   3. INDEXED CLASSIFICATIONS (P, T, E, S)
   ========================================================================== */

% PERSPECTIVE 1: NOVEL DRUG DEVELOPER (SNARE) — The widespread adoption of a cheap generic for prevention would suppress the market for novel, patent-protected Alzheimer's drugs, trapping billions in R&D investment. Their exit is constrained by sunk costs and long research cycles. d is high due to victim status, leading to χ > 0.66.
constraint_indexing:constraint_classification(alzheimers_levetiracetam, snare,
    context(agent_power(institutional),
            time_horizon(generational),
            exit_options(constrained),
            spatial_scope(global))).

% PERSPECTIVE 2: AT-RISK PATIENT (ROPE) — From the perspective of an individual with high genetic risk, this is a pure coordination good: a cheap, accessible, and potentially effective way to prevent a devastating disease. As a beneficiary with mobile exit (they can choose not to take it), their d is low, resulting in a low, or even negative, effective extraction χ.
constraint_indexing:constraint_classification(alzheimers_levetiracetam, rope,
    context(agent_power(organized),
            time_horizon(biographical),
            exit_options(mobile),
            spatial_scope(national))).

% PERSPECTIVE 3: ANALYTICAL OBSERVER (TANGLED ROPE) — The analyst sees both the massive coordination benefit (preventing Alzheimer's at population scale for low cost) and the severe extraction (chilling effect on future pharmaceutical R&D). The high base extraction and suppression, combined with a genuine coordination function, meet the Tangled Rope criteria.
constraint_indexing:constraint_classification(alzheimers_levetiracetam, tangled_rope,
    context(agent_power(analytical),
            time_horizon(civilizational),
            exit_options(analytical),
            spatial_scope(global))).

% PERSPECTIVE 4: REGULATORY AGENCY (SCAFFOLD) — A regulator might view off-label guidance or provisional approval as a temporary measure (Scaffold) to bridge the gap until more effective, targeted drugs are developed and proven. The 'sunset clause' is the eventual arrival of a superior, fully-vetted therapy, at which point this stopgap measure would be superseded.
constraint_indexing:constraint_classification(alzheimers_levetiracetam, scaffold,
    context(agent_power(institutional),
            time_horizon(generational),
            exit_options(constrained),
            spatial_scope(national))).

/* ==========================================================================
   4. VALIDATION TESTS
   ========================================================================== */

:- begin_tests(alzheimers_levetiracetam_tests).

test(extraction_signature) :-
    domain_priors:base_extractiveness(alzheimers_levetiracetam, E),
    E >= 0.46. % Ensures high-extraction Snare/Tangled territory.

:- end_tests(alzheimers_levetiracetam_tests).

/* ==========================================================================
   5. GENERATIVE COMMENTARY
   ========================================================================== */

/**
 * LOGIC RATIONALE:
 *   Extractiveness (ε=0.55): This value does not represent the cost of the drug, which is low. It represents the high opportunity cost imposed on the developers of novel therapies, whose potential market is effectively 'extracted' by the generic alternative. Suppression (0.65): High. The existence of a 'good enough' cheap preventative creates a formidable barrier to funding, regulatory approval, and market adoption for expensive new drugs, which would need to demonstrate overwhelming superiority to compete.
 *
 * PERSPECTIVAL GAP:
 *   The gap is stark. For patients, this is a Rope—a simple tool for coordinating a defense against disease. For the pharmaceutical companies invested in novel solutions, it is a Snare—a market-destroying trap they are powerless to escape due to long R&D cycles. The analytical observer, seeing both the potential public good and the chilling effect on innovation, correctly identifies the hybrid Tangled Rope structure. Regulators may see it as a temporary Scaffold, a stopgap until better options are proven.
 *
 * DIRECTIONALITY LOGIC:
 *   Beneficiaries (patients, public health) experience the constraint as a coordination mechanism, leading to a low derived directionality (d) and low effective extraction (χ). Victims (novel drug developers) experience it as pure, coercive extraction. Their victim status and constrained exit options lead to a high d value, which, when multiplied by the high base extractiveness (ε), results in a χ value that crosses the Snare threshold.
 *
 * MANDATROPHY ANALYSIS:
 *   This case is a clear example of how Deferential Realism resolves mandatrophy. A simplistic analysis would frame this as 'cheap generic good, expensive pharma bad'. The DR framework avoids this by quantifying the structural dynamics. It shows that the same policy can be simultaneously a Rope (for patients) and a Snare (for innovators). The core conflict is not one of morals but of a Tangled Rope structure, where a genuine coordination function is inextricably linked to a powerful, asymmetric extraction. The correct policy response is not to pick a side, but to manage the tensions of the Tangled Rope itself.
 */

/* ==========================================================================
   6. OMEGA VARIABLES (Ω) - IRREDUCIBLE UNCERTAINTIES
   ========================================================================== */

omega_variable(
    true_preventative_efficacy,
    'What is the true, long-term preventative efficacy of low-dose levetiracetam in the general at-risk population, when initiated decades before symptom onset?',
    'A multi-decade, large-scale, randomized controlled trial, which is prohibitively expensive and complex to conduct.',
    'High efficacy would validate the Rope/Scaffold perspectives and justify the R&D suppression. Low or zero efficacy would confirm it as a Snare, imposing costs (side effects, false hope) for no benefit.',
    confidence_without_resolution(high)
).

narrative_ontology:omega_variable(true_preventative_efficacy, empirical, 'Actual long-term preventative efficacy in the general population.').

omega_variable(
    rd_chilling_effect,
    'To what extent would the widespread adoption of a cheap generic actually suppress private investment in novel Alzheimer''s drug research?',
    'Economic modeling of pharmaceutical R&D investment decisions under scenarios of generic competition; historical analysis of similar cases in other disease areas.',
    'A high chilling effect confirms the Snare perspective for developers and the high extraction score. A low effect would suggest the constraint is closer to a pure Rope.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(rd_chilling_effect, empirical, 'Quantifying the suppression of R&D for novel drugs.').

omega_variable(
    long_term_safety_profile,
    'What are the unknown health risks of taking a neurologically active drug for 20-40 years by a population that is largely healthy at the start of treatment?',
    'Longitudinal safety data from the aforementioned hypothetical multi-decade trial.',
    'Discovery of significant long-term side effects would dramatically increase the extraction borne by patients, strengthening the Snare classification from their perspective.',
    confidence_without_resolution(high)
).

narrative_ontology:omega_variable(long_term_safety_profile, empirical, 'Unknown risks of multi-decade use in a healthy population.').


/* ==========================================================================
   7. INTEGRATION HOOKS
   ========================================================================== */

narrative_ontology:interval(alzheimers_levetiracetam, 2020, 2040).

/* ==========================================================================
   8. TEMPORAL MEASUREMENTS (LIFECYCLE DRIFT DATA)
   ========================================================================== */

% Theater ratio over time
narrative_ontology:measurement(alzh_tr_t0, alzheimers_levetiracetam, theater_ratio, 0, 0.1).
narrative_ontology:measurement(alzh_tr_t10, alzheimers_levetiracetam, theater_ratio, 10, 0.15).
narrative_ontology:measurement(alzh_tr_t20, alzheimers_levetiracetam, theater_ratio, 20, 0.2).

% Extraction over time
narrative_ontology:measurement(alzh_be_t0, alzheimers_levetiracetam, base_extractiveness, 0, 0.25).
narrative_ontology:measurement(alzh_be_t10, alzheimers_levetiracetam, base_extractiveness, 10, 0.45).
narrative_ontology:measurement(alzh_be_t20, alzheimers_levetiracetam, base_extractiveness, 20, 0.55).


/* ==========================================================================
   9. BOLTZMANN & NETWORK DATA
   ========================================================================== */

narrative_ontology:coordination_type(alzheimers_levetiracetam, resource_allocation).
narrative_ontology:affects_constraint(alzheimers_levetiracetam, pharmaceutical_patent_cliffs).
narrative_ontology:affects_constraint(alzheimers_levetiracetam, fda_approval_process).

/* ==========================================================================
   10. DIRECTIONALITY OVERRIDES (v6.0, OPTIONAL)
   ========================================================================== */

/* ==========================================================================
   END OF CONSTRAINT STORY
   ========================================================================== */
